Login to Your Account



Is Gene Therapy Back in Style for VCs? GenSight Lands $42M

By Nuala Moran
Staff Writer

Wednesday, April 10, 2013
Gene therapy start-up GenSight Biologics has raised €32 million (US$41 .6 million) in a Series A funding, hinting that following on from the first European regulatory approval of a gene therapy and with an increasing volume of positive clinical data, this iconic field is now de-risked in the eyes of venture capital investors.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription